Publications

Gentry R, Thompson CM, Franzen A, Salley J, Albertini R, Lu K, Greene T. 2020. Using mechanistic information to support evidence integration and synthesis: A case study with inhaled formaldehyde and leukemia. Crit Rev Toxicol 50(10):885–918; doi: 10.1080/10408444.2020.1854678.

Nelms MD, Patlewicz G. 2020. Derivation of new threshold of toxicological concern values for exposure via inhalation for environmentally-relevant chemicals. Front Toxicol 2:580347; doi: 10.3389/ftox.2020.580347. PMID: 35296122.

Halbert RJ, Nordyke RJ, Nicholson G, Pilgrim A, Niklason L. 2020. Patency of ePTFE arteriovenous graft placements in hemodialysis patients: Systematic literature review and meta-analysis. Kidney360 1(12):1437–1446; doi: 10.34067/KID.0003502020. PMID: 35372887.

Parker J, Boles C, Leleck O, Buerger AN, Egnot N, Sunderman A, et al. 2020. Advancing toward normal operations for arenas and stadiums. Toxicol Ind Health 36(9):718–727; doi: 10.1177/0748233720964651.

Wikoff D, Lewis JR, Erraguntla N, Franzen A, Foreman J. 2020. Facilitation of risk assessment with evidence-based methods — A framework for use of systematic mapping and systematic reviews in determining hazard, developing toxicity values, and characterizing uncertainty. Regul Toxicol Pharmacol 118:104790; doi: 10.1016/j.yrtph.2020.104790. PMID: 33038430.

Flythe JE, Hilliard TS, Ikeler K, Keller S, Gipson DS, Grandinetti AC, Nordyke RJ, Perrone RD, et al. 2020. Toward patient-centered innovation: A conceptual framework for patient-reported outcome measures for transformative kidney replacement devices. Clin J Am Soc Nephrol 15(10):1522-1530; doi: 10.2215/CJN.00110120. PMID: 32276947.

Cohen SS, Roger VL, Weston SA, Jiang R, Movva N, Yusuf AA, Chamberlain AM. 2020. Evaluation of claims-based computable phenotypes to identify heart failure patients with preserved ejection fraction. Pharmacol Res Persp 8(6):e00676; doi: 10.1002/prp2.676.

Guo X, Seo JE, Petibone D, Tryndyak V, Lee UJ, Zhou T, Robison TW, Mei N. 2020. Performance of HepaRG and HepG2 cells in the high-throughput micronucleus assay for in vitro genotoxicity assessment. J Toxicol Environ Health A 83(21-22):702-717; doi: 10.1080/15287394.2020.1822972.

Brown L, Lynch M, Belova A, Klein R, Chiger A. 2020. Developing a health impact model for adult lead exposure and cardiovascular disease mortality. Environ Health Persp 128(9):97005; doi: 10.1289/EHP6552. PMID: 32965128.

Jackson AC, Liu J, Vallanat B, Jones C, Nelms MD, Patlewicz G, Corton JC. 2020. Identification of novel activators of the metal responsive transcription factor (MTF-1) using a gene expression biomarker in a microarray compendium. Metallomics 12(9):1400-1415; doi: 10.1039/d0mt00071j. PMID: 32661532.

Wheeler MW, Blessinger T, Shao K, Allen BC, Olszyk L, Davis JA, Gift JS. 2020. Quantitative risk assessment: Developing a Bayesian approach to dichotomous dose–response uncertainty. Risk Anal 40(9):1706-22; doi: 10.1111/risa.13537. PMCID: PMC7722241.

Kieran TJ, Goodman SJ, Finger JW Jr, Thomas JC 4^th, Hamilton MT, Tuberville TD, Glenn TC. 2020. Microbiota of four tissue types in American alligators (Alligator mississippiensis) following extended dietary selenomethionine exposure. Bull Environ Contam Toxicol 105(3):381-386; doi: 10.1007/s00128-020-02961-3. PMID: 32794125.

Bylsma LC, Gillezeau C, Garawin TA, Kelsh MA, Fryzek JP, Sangaré L, et al. 2020. Prevalence of RAS and BRAF mutations in metastatic colorectal cancer patients by tumor sidedness: A systematic review and meta-analysis. Cancer Med 9(3):1044–1057.

Li S, Liu J, Gong T, Guo H, Gawade PL, Kelsh MA, et al. 2020. Duration of short-acting granulocyte colony-stimulating factor for primary prophylaxis and risk of neutropenia-related hospitalization in older patients with cancer. J Geriatr Oncol 11(8):1309–1315.

Li S, Peng Y, Liu J, Li S, Raskin L, Kelsh MA, et al. Variations in hospitalization and emergency department/observation stays using the oncology care model methodology in Medicare data. 2020. Curr Med Res Opin 36(9):1519–1527.

Gawade PL, Li S, Henry D, Smith N, Belani R, Kelsh MA, et al. Patterns of granulocyte colony-stimulating factor prophylaxis in patients with cancer receiving myelosuppressive chemotherapy. 2020. Support Care Cancer 28(9):4413–4424.

Hawkins A, Murphy A, McNamara M, Gawade PL, Belani R, Kelsh MA. 2020. A survey of oncologists’ perceptions and opinions regarding the use of granulocyte colony-stimulating factors. J Cancer Edu 35(1):178–186.

Locatelli F, Whitlock JA, Peters C, Chen-Santel C, Chia V, Dennis RM, … Kelsh MA, et al. 2020. Blinatumomab versus historical standard therapy in pediatric patients with relapsed/refractory Ph-negative B-cell precursor acute lymphoblastic leukemia. Leukemia 34(9):2473–2478; doi: 10.1038/s41375-020-0770-8. PMID: 32094465.

Eichenbaum G, Yang K, Gebremichael Y, Howell BA, Murray FJ, Jacobson-Kram D, Jaeschke H, Kuffner E, Gelotte CK, Lai JCK, Wikoff D, Atillasoy E. 2020. Application of the DILIsym® Quantitative Systems Toxicology drug-induced liver injury model to evaluate the carcinogenic hazard potential of acetaminophen. Regul Toxicol Pharmacol 118(Dec):104788; doi: 10.1016/j.yrtph.2020.104788.

Fryzek J, Bylsma L, Mease K, Movva N, Welsh BT, Wood M. 2020. Critical insights into nonclinical toxicology and real-world evidence essential for a successful rare disease product launch. EpidStrategies, Inc. White Paper.